Objective: To explore the potential classroom furniture mismatch with students’ anthropometric measurements and back pain related to sitting for extended periods. Methods: This cross-sectional study was carried out on all twelve male and female intermediate and secondary schools located in Abha city. Anthropometric and classroom furniture measurements were assessed, and the mismatch was determined using standardized methods. Students were also screened for back pain related to long sitting at school. Results: A total number of 879 students was selected. The study revealed seat height mismatch in both intermediate, and secondary school of 84.3%, and 75.6%, respectively. Seat depth mismatch was 74.0% in intermediate schools and reached 84.5% in secondary schools. The desk height was improper for 94.1%, and 82.3% of students in intermediate, and secondary schools, respectively. The levels of mismatch differ significantly by grade level and gender. A prevalence of 10.8% of back pain related to long sitting at school was found. In multivariable logistic regression, males, intermediate school children, and the presence of buttock-popliteal length/seat depth mismatch were significantly associated with pain. On the other hand, practicing exercise was a significant protective factor. Conclusions: There is a prevalent mismatch between students’ dimensions and existing schools’ furniture. School furniture providers should take in consideration the average Saudi students’ dimensions, while designing school furniture especially for males, and at intermediate schools, or provide schools with adjustable seats and desks.

No abstract

Background Psoriatic arthritis (PsA) is a challenging heterogeneous disease. The European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) last published their respective recommendations for the management of PsA in 2015. However, these guidelines are primarily based on studies conducted in resource replete countries and may not be applicable in countries in the Americas (except Canada and USA) and Africa. We sought to adapt the existing recommendations for these regions under the auspices of the International League of Associations for Rheumatology (ILAR). Process The ADAPTE Collaboration (2009) process for guideline adaptation was followed to adapt the EULAR and GRAPPA PsA treatment recommendations for the Americas and Africa. The process was conducted in three recommended phases: setup phase; adaptation phase (defining health questions, assessing source recommendations, drafting report), and finalization phase (external review, aftercare planning, and final production). Result ILAR recommendations have been derived principally by adapting the GRAPPA recommendations, additionally, EULAR recommendations where appropriate and supplemented by expert opinion and literature from these regions. A paucity of data relevant to resource-poor settings was found in PsA management literature. Conclusion The ILAR Treatment Recommendations for PsA intends to serve as reference for the management of PsA in the Americas and Africa. This paper illustrates the experience of an international working group in adapting existing recommenda

No abstract

ObjectiveThis literature review aimed to identify the most efficacious current interventions for dactylitis and provide up-to-date scientific evidence to support the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations on the management of psoriatic arthritis.MethodsOriginal articles published from 2013 to 2020, registered in MEDLINE, Embase, and Cochrane Library, describing interventional trials and reporting dactylitis-related outcomes were included. The 20 members of the GRAPPA dactylitis group were divided into 9 subgroups according to treatment, and members of each group independently extracted data from articles/abstracts corresponding to their group by using a standardized data extraction form.ResultsForty-nine publications were analyzed, representing 40 randomized clinical trials (RCTs) and including 16,752 patients. Dactylitis was assessed as a secondary outcome in 97.5% of these trials and more than 40% of RCTs did not employ a specific dactylitis measure or instrument.ConclusionThe emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis. This article points out the lack of consensus regarding dactylitis assessment and the paucity of data concerning the effect of local steroid injections, nonsteroidal antiinflammatory drugs, and conventional disease-modifying antirheumatic drugs. Clinical trials evaluating the effect of these traditional and low-cost medications used to treat dactylitis should be encouraged.